Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated by Analysts at Leerink Partners

Leerink Partners assumed coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX) in a research report sent to investors on Wednesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $23.00 target price on the stock.

Other equities analysts have also recently issued research reports about the company. Zacks Research cut Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday. Barclays increased their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. UBS Group boosted their target price on shares of Amneal Pharmaceuticals from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 26th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $17.25 on Wednesday. Amneal Pharmaceuticals has a 52 week low of $9.49 and a 52 week high of $19.26. The firm has a market capitalization of $5.51 billion, a P/E ratio of 35.20 and a beta of 1.24. The company has a fifty day simple moving average of $17.77 and a two-hundred day simple moving average of $15.01. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Analysts anticipate that Amneal Pharmaceuticals will post 0.94 earnings per share for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director John Kiely sold 50,000 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the sale, the director owned 210,252 shares in the company, valued at $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jason B. Daly sold 210,000 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $17.40, for a total value of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares in the company, valued at $611,975.40. This trade represents a 85.65% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 413,016 shares of company stock valued at $7,216,567. Company insiders own 17.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System grew its position in shares of Amneal Pharmaceuticals by 1,592.8% in the 2nd quarter. California State Teachers Retirement System now owns 3,508,079 shares of the company’s stock worth $60,725,000 after buying an additional 3,300,840 shares during the last quarter. Westshore Wealth LLC acquired a new stake in Amneal Pharmaceuticals in the third quarter valued at approximately $13,833,000. Morgan Stanley boosted its stake in Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after acquiring an additional 1,315,018 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Amneal Pharmaceuticals by 72.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock worth $32,405,000 after purchasing an additional 1,069,400 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Amneal Pharmaceuticals during the second quarter worth $17,573,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.